

Nevada Provider Communications

Updates to AIM Advanced Oncologic Imaging Clinical Appropriateness Guideline

Published: Aug 1, 2019

Effective for dates of service on and after July 14, 2019, the following updates will apply to the AIM Advanced Oncologic Imaging Clinical Appropriateness Guideline.

- **Prostate Cancer:** Added criteria for the appropriate use of PET-CT with the radiotracers Axumin and 11-Choline, establishing the position of this test in the care continuum for prostate cancer primarily related to biochemical recurrence
- **Neuroendocrine Tumors:** Added criteria for the appropriate use of PET-CT with the radiotracer DOTA-TATE, establishing the position of this test in the care continuum for neuroendocrine tumors

As a reminder, ordering and servicing providers may submit pre-certification requests to AIM in one of several ways:

- Access AIM **ProviderPortalSM** directly at providerportal.com. Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at availity.com
- Call the AIM Contact Center toll-free number: 877-291-0366, Monday - Friday, 7:00 a.m. - 5:00 p.m. PT.

For questions related to guideline updates, please contact AIM via email at aim.guidelines@aimspecialtyhealth.com. To access and download a copy of the current guidelines, go to: <http://www.aimspecialtyhealth.com/ClinicalGuidelines.html>.

<https://providernews.anthem.com/nevada/article/updates-to-aim-advanced-oncologic-imaging-clinical-appropriateness-guideline-6>

Featured In:

August 2019 Anthem Provider News and Important Updates - Nevada